Baidu
map

盘点:近期与乳腺癌相关研究汇总

2016-11-29 MedSci MedSci原创

乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。全球乳腺癌发病率自20世纪70年代末开始一直呈上升趋势;我国乳腺癌的发病率也逐年上升,每年有近20万女性被诊断出乳腺癌。从死亡率的曲线也可以看出,随着新的治疗策略和方法的普及,虽然全球乳腺癌的死亡率逐步下降,但中国乳腺癌死亡率的下降趋势不显著。本文梅斯医学小编就近期乳腺癌相关研究进行盘点。【1】RSNA 2016:女性到了75岁是不是就可以停止乳腺癌的筛

乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。全球乳腺癌发病率自20世纪70年代末开始一直呈上升趋势;我国乳腺癌的发病率也逐年上升,每年有近20万女性被诊断出乳腺癌。从死亡率的曲线也可以看出,随着新的治疗策略和方法的普及,虽然全球乳腺癌的死亡率逐步下降,但中国乳腺癌死亡率的下降趋势不显著。本文梅斯医学小编就近期乳腺癌相关研究进行盘点。

【1】RSNA 2016:女性到了75岁是不是就可以停止乳腺癌的筛查了?

近日,来自加利福尼亚大学的一项新的研究表明,目前仍未有足够的证据表明女性在达到一特定年龄后可停止乳腺癌的筛查。该研究是迄今为止美国最大的乳腺钼靶摄影研究结果,其研究结果已在美国北美放射学会(RSNA)年会上展示。

研究人员分析了来自美国国家乳腺钼靶摄影数据库的数据,评估了超过560万个筛选项目,包括250万名女性,年龄在40岁以上。将这些女性进行分组,以5岁的年龄间隔进行分组,上限年龄为90岁,分为40-44岁,45-49,50-54,55-59年龄组等等。每1000名患者中,研究人员确定了总的平均癌症检出率为3.74,召回率为10%,PPV2率为20%,以及PPV3率为29%。

研究人员发现,随着年龄的增加,癌症的检出率也在增加,PPV2和PPV3率也在逐步上升,而召回率则在下降,这些结果都符合理想筛查的标准。

最后研究人员总结道该研究结果支持女性可根据自身的健康状况和个人喜好来做出决定,决定自己≥75岁时是否中止或继续行乳腺癌筛查。不过仍有必要行进一步的调查研究,新的研究表明,74岁之后行乳腺癌筛查其利大于弊。(文章详见--RSNA 2016:女性到了75岁是不是就可以停止乳腺癌的筛查了?

【2】Lancet:对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好

芳香酶抑制剂是激素受体阳性的局部晚期或转移性乳腺癌的一种标准治疗方案。近日,顶级医学杂志Lancet上发表了一篇研究文章,旨在评估相比于阿那曲唑,选择性雌激素受体的降解物氟维司群能否改善没有接受过内分泌治疗的绝经患者的无进展生存期。

在2014年7月11日至2012年10月17日期间,共有524例患者参加了这项研究。其中,462例患者被随机分配(230名接受氟维司群和232名接受阿那曲唑)。接受氟维司群治疗的患者无进展生存期明显长于接受阿那曲唑治疗的患者(风险比为0.797,95%可信区间为0.637–0.999,P=0.0486)。接受氟维司群治疗的患者中位无进展生存期为16.6个月(95%可信区间为13.83–20.99),而在接受阿那曲唑治疗的患者为13.8个月(11.99–16.59)。最常见的不良反应是关节痛(接受氟维司群治疗的患者中有38例[17%],接受阿那曲唑治疗的患者有24例[10%])、潮热(接受氟维司群治疗的患者中有26例[11%],接受阿那曲唑治疗的患者有24例[10%])。16(7%)例/228例接受氟维司群治疗的患者和11(5%)例/232例接受阿那曲唑治疗的患者因不良事件而终止试验。

由此可见,对于没有接受过内分泌治疗的激素受体阳性的局部晚期或转移性乳腺癌患者,相比于用于这些患者的一线治疗的标准治疗药物-第三代芳香化酶抑制剂,氟维司群具有优越的疗效并且可以作为这些患者的首选治疗药物。(文章详见--Lancet:对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好

【3】Oncogene:又一项“饿死”癌细胞疗法 杀死难治性乳腺癌

杜克大学的科学家在Oncogene发表的一项新研究报道称,一种恶性和耐药性乳腺癌(称为三阴性乳腺癌,TNBC)的细胞,当被剥夺称为胱氨酸的关键营养物质时,会迅速死去。通过研究细胞死亡的原因,他们发现,这个“胱氨酸瘾”是由一种机制触发的,多种肿瘤细胞用这种机制来脱离和迁移到新的身体部位。  

这项研究的资深作者、杜克大学分子遗传学和微生物学副教授Jen-Tsan Ashley Chi说:“这个过程是众所周知的,并显现在转移性癌细胞中,我们发现,这也使得细胞对胱氨酸上瘾了。这是一则好消息,因为这些都是我们真正想摆脱的细胞。”  

这些结果表明,阻断胱氨酸摄取,不仅是治疗三阴性乳腺癌的有效方法,而且也能治疗其他在转移过程中使用这一路径的恶性肿瘤。  

被诊断为三阴性乳腺癌的患者,占所有乳腺癌患者的百分之10至百分之20,除了手术和化疗之外很少有治疗方案。这是因为,大多数成功的乳腺癌疗法,都是靶定肿瘤细胞中普遍存在的三个受体(雌激素受体、孕酮受体或Her2/neu受体)中的两个,但是三阴性乳腺癌细胞缺乏这三个受体。(文章详见--Oncogene:又一项“饿死”癌细胞疗法 杀死难治性乳腺癌

【4】2016 NCCN临床实践指南:乳腺癌-证据块(2016.V2)

2016年11月,美国国家综合癌症网络(NCCN)发布了乳腺癌指南证据块2016年第2版。(指南详见

【5】2016 ACR适宜性标准:乳腺癌筛查、

乳腺钼靶检查是一般女性人群乳腺癌建议的筛查方法,针对高风险人群的筛查建议采用MRI和超声检查作为补充检查技术。本文主要介绍了以上3种检查方法以及其他影像学检查方法在乳腺癌筛查中的应用。 (指南详见

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1800428, encodeId=219e1800428c6, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 18 22:28:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166878, encodeId=eb3e1668e8d6, content=喜欢原版的?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=025a2003248, createdName=于平, createdTime=Fri Dec 30 20:22:43 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161509, encodeId=a23e1615091f, content=学习并收藏了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:48:57 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159405, encodeId=63c81594055e, content=知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161129/IMG583D61B4B08EB5084.jpg, createdBy=89f71988067, createdName=1e19acbam91(暂无匿称), createdTime=Thu Dec 01 11:45:23 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159118, encodeId=982315911831, content=小编辛苦了!为我们整理如此齐全的资料,供学习探究。点赞啦!谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Nov 30 09:02:52 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159105, encodeId=fd4c159105dd, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Nov 30 08:45:54 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159092, encodeId=358415909277, content=学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed Nov 30 08:01:58 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158971, encodeId=c0241589e1b2, content=总结得太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:44:53 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1800428, encodeId=219e1800428c6, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 18 22:28:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166878, encodeId=eb3e1668e8d6, content=喜欢原版的?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=025a2003248, createdName=于平, createdTime=Fri Dec 30 20:22:43 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161509, encodeId=a23e1615091f, content=学习并收藏了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:48:57 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159405, encodeId=63c81594055e, content=知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161129/IMG583D61B4B08EB5084.jpg, createdBy=89f71988067, createdName=1e19acbam91(暂无匿称), createdTime=Thu Dec 01 11:45:23 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159118, encodeId=982315911831, content=小编辛苦了!为我们整理如此齐全的资料,供学习探究。点赞啦!谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Nov 30 09:02:52 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159105, encodeId=fd4c159105dd, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Nov 30 08:45:54 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159092, encodeId=358415909277, content=学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed Nov 30 08:01:58 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158971, encodeId=c0241589e1b2, content=总结得太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:44:53 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-12-30 于平

    喜欢原版的?!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1800428, encodeId=219e1800428c6, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 18 22:28:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166878, encodeId=eb3e1668e8d6, content=喜欢原版的?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=025a2003248, createdName=于平, createdTime=Fri Dec 30 20:22:43 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161509, encodeId=a23e1615091f, content=学习并收藏了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:48:57 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159405, encodeId=63c81594055e, content=知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161129/IMG583D61B4B08EB5084.jpg, createdBy=89f71988067, createdName=1e19acbam91(暂无匿称), createdTime=Thu Dec 01 11:45:23 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159118, encodeId=982315911831, content=小编辛苦了!为我们整理如此齐全的资料,供学习探究。点赞啦!谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Nov 30 09:02:52 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159105, encodeId=fd4c159105dd, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Nov 30 08:45:54 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159092, encodeId=358415909277, content=学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed Nov 30 08:01:58 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158971, encodeId=c0241589e1b2, content=总结得太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:44:53 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-12-09 ys2323

    学习并收藏了!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1800428, encodeId=219e1800428c6, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 18 22:28:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166878, encodeId=eb3e1668e8d6, content=喜欢原版的?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=025a2003248, createdName=于平, createdTime=Fri Dec 30 20:22:43 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161509, encodeId=a23e1615091f, content=学习并收藏了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:48:57 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159405, encodeId=63c81594055e, content=知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161129/IMG583D61B4B08EB5084.jpg, createdBy=89f71988067, createdName=1e19acbam91(暂无匿称), createdTime=Thu Dec 01 11:45:23 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159118, encodeId=982315911831, content=小编辛苦了!为我们整理如此齐全的资料,供学习探究。点赞啦!谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Nov 30 09:02:52 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159105, encodeId=fd4c159105dd, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Nov 30 08:45:54 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159092, encodeId=358415909277, content=学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed Nov 30 08:01:58 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158971, encodeId=c0241589e1b2, content=总结得太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:44:53 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-12-01 1e19acbam91(暂无匿称)

    知道了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1800428, encodeId=219e1800428c6, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 18 22:28:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166878, encodeId=eb3e1668e8d6, content=喜欢原版的?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=025a2003248, createdName=于平, createdTime=Fri Dec 30 20:22:43 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161509, encodeId=a23e1615091f, content=学习并收藏了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:48:57 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159405, encodeId=63c81594055e, content=知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161129/IMG583D61B4B08EB5084.jpg, createdBy=89f71988067, createdName=1e19acbam91(暂无匿称), createdTime=Thu Dec 01 11:45:23 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159118, encodeId=982315911831, content=小编辛苦了!为我们整理如此齐全的资料,供学习探究。点赞啦!谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Nov 30 09:02:52 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159105, encodeId=fd4c159105dd, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Nov 30 08:45:54 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159092, encodeId=358415909277, content=学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed Nov 30 08:01:58 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158971, encodeId=c0241589e1b2, content=总结得太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:44:53 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-11-30 ylzr123

    小编辛苦了!为我们整理如此齐全的资料,供学习探究。点赞啦!谢谢!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1800428, encodeId=219e1800428c6, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 18 22:28:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166878, encodeId=eb3e1668e8d6, content=喜欢原版的?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=025a2003248, createdName=于平, createdTime=Fri Dec 30 20:22:43 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161509, encodeId=a23e1615091f, content=学习并收藏了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:48:57 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159405, encodeId=63c81594055e, content=知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161129/IMG583D61B4B08EB5084.jpg, createdBy=89f71988067, createdName=1e19acbam91(暂无匿称), createdTime=Thu Dec 01 11:45:23 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159118, encodeId=982315911831, content=小编辛苦了!为我们整理如此齐全的资料,供学习探究。点赞啦!谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Nov 30 09:02:52 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159105, encodeId=fd4c159105dd, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Nov 30 08:45:54 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159092, encodeId=358415909277, content=学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed Nov 30 08:01:58 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158971, encodeId=c0241589e1b2, content=总结得太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:44:53 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-11-30 1dd8c52fm63(暂无匿称)

    了解了解!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1800428, encodeId=219e1800428c6, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 18 22:28:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166878, encodeId=eb3e1668e8d6, content=喜欢原版的?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=025a2003248, createdName=于平, createdTime=Fri Dec 30 20:22:43 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161509, encodeId=a23e1615091f, content=学习并收藏了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:48:57 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159405, encodeId=63c81594055e, content=知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161129/IMG583D61B4B08EB5084.jpg, createdBy=89f71988067, createdName=1e19acbam91(暂无匿称), createdTime=Thu Dec 01 11:45:23 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159118, encodeId=982315911831, content=小编辛苦了!为我们整理如此齐全的资料,供学习探究。点赞啦!谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Nov 30 09:02:52 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159105, encodeId=fd4c159105dd, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Nov 30 08:45:54 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159092, encodeId=358415909277, content=学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed Nov 30 08:01:58 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158971, encodeId=c0241589e1b2, content=总结得太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:44:53 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-11-30 laoli

    学习了!谢谢分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1800428, encodeId=219e1800428c6, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Dec 18 22:28:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=166878, encodeId=eb3e1668e8d6, content=喜欢原版的?!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=025a2003248, createdName=于平, createdTime=Fri Dec 30 20:22:43 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161509, encodeId=a23e1615091f, content=学习并收藏了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:48:57 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159405, encodeId=63c81594055e, content=知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161129/IMG583D61B4B08EB5084.jpg, createdBy=89f71988067, createdName=1e19acbam91(暂无匿称), createdTime=Thu Dec 01 11:45:23 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159118, encodeId=982315911831, content=小编辛苦了!为我们整理如此齐全的资料,供学习探究。点赞啦!谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed Nov 30 09:02:52 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159105, encodeId=fd4c159105dd, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Nov 30 08:45:54 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159092, encodeId=358415909277, content=学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Wed Nov 30 08:01:58 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158971, encodeId=c0241589e1b2, content=总结得太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b4c1651704, createdName=1ddcba5em94(暂无匿称), createdTime=Tue Nov 29 21:44:53 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-11-29 1ddcba5em94(暂无匿称)

    总结得太好了

    0

相关资讯

RSNA 2016:女性到了75岁是不是就可以停止乳腺癌的筛查了?

近日,来自加利福尼亚大学的一项新的研究表明,目前仍未有足够的证据表明女性在达到一特定年龄后可停止乳腺癌的筛查。该研究是迄今为止美国最大的乳腺钼靶摄影研究结果,其研究结果已在美国北美放射学会(RSNA)年会上展示。研究人员分析了来自美国国家乳腺钼靶摄影数据库的数据,评估了超过560万个筛选项目,包括250万名女性,年龄在40岁以上。将这些女性进行分组,以5岁的年龄间隔进行分组,上限年龄为90岁,分为

2016 ACR适宜性标准:乳腺癌筛查

乳腺钼靶检查是一般女性人群乳腺癌建议的筛查方法,针对高风险人群的筛查建议采用MRI和超声检查作为补充检查技术。本文主要介绍了以上3种检查方法以及其他影像学检查方法在乳腺癌筛查中的应用。  下载地址:下载   (需要扣积分2分, 梅斯医学APP免积分下载) 

2016 NCCN临床实践指南:乳腺癌-证据块(2016.V2)

2016年11月,美国国家综合癌症网络(NCCN)发布了乳腺癌指南证据块2016年第2版。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载) 

盘点:近期乳腺癌研究精华汇总

乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。全球乳腺癌发病率自20世纪70年代末开始一直呈上升趋势;我国乳腺癌的发病率也逐年上升,每年有近20万女性被诊断出乳腺癌。从死亡率的曲线也可以看出,随着新的治疗策略和方法的普及,虽然全球乳腺癌的死亡率逐步下降,但中国乳腺癌死亡率的下降趋势不显著。本文梅斯医学小编就近期乳腺癌相关研究进行盘点。【1】Cancer Res:三阴性乳腺癌转移必需蛋白BRD4被发现

PNAS:肿瘤细胞或可“拆用”间充质干细胞来促进乳腺癌复发

为何很多乳腺癌幸存者都非常担心会发生疾病复发呢?这一问题也让很多科学家和卫生保健提供者非常困扰,因为乳腺癌患者在进行治疗结束后的数年里癌症会突然间死灰复燃,最终导致患者死亡。近日刊登在国际杂志Proceedings of the National Academy of Sciences上的一项研究报告中,来自德州农工大学医学院的研究人员通过研究发现,乳腺癌患者机体中休眠的肿瘤细胞往往会潜伏起来,因

Lancet:对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好

对于没有接受过内分泌治疗的激素受体阳性的局部晚期或转移性乳腺癌患者,相比于用于这些患者的一线治疗的标准治疗药物-第三代芳香化酶抑制剂,氟维司群具有优越的疗效并且可以作为这些患者的首选治疗药物。

Baidu
map
Baidu
map
Baidu
map